Home    Back

Metoprolol succinate    (DrugBank: Metoprolol)

4 diseases
IDDisease name (Link within this page)Number of trials
57Idiopathic dilated cardiomyopathy1
58Hypertrophic cardiomyopathy2
113Muscular dystrophy1
193Prader-Willi syndrome1

57. Idiopathic dilated cardiomyopathy    [ 12 clinical trials,   25 drugs,   (DrugBank: 12 drugs),   9 drug target genes,   33 drug target pathways]
Searched query = "Idiopathic dilated cardiomyopathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 12 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01798992
(ClinicalTrials.gov)		September 200022/2/2013Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human HeartBeta-blocker Effect on Structural Remodeling and Gene Expression in the Failing Human HeartIdiopathic Dilated CardiomyopathyDrug: Carvedilol;Drug: Metoprolol succinate;Drug: Metoprolol succinate + doxazosinUniversity of Colorado, DenverNational Heart, Lung, and Blood Institute (NHLBI);GlaxoSmithKline;AstraZenecaCompleted18 YearsN/AAll56Phase 4United States

58. Hypertrophic cardiomyopathy    [ 92 clinical trials,   126 drugs,   (DrugBank: 35 drugs),   40 drug target genes,   141 drug target pathways]
Searched query = "Hypertrophic cardiomyopathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 92 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1ChiCTR-IIR-17013661
2018-10-102017-12-03Effect of beta-blockers combined with angiotensin II receptor blockers in regression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy: A multicenter randomized, controlled clinical trialEffect of beta-blockers combined with angiotensin II receptor blockers in regression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy: A multicenter randomized, controlled clinical trial Hypertrophic cardiomyopathyExperimental group:Metoprolol Succinate Sustained-release Tablets combined with candesartan treatment;Control group:Metoprolol Succinate Sustained-release Tablets monotherapy;The First Affiliated Hospital, Sun Yat-sen UniversityNULLRecruiting1865BothExperimental group:130;Control group:130;4 (Phase 4 study)China
2NCT03532802
(ClinicalTrials.gov)		May 1, 201819/4/2018The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.The Effect of Metoprolol on Myocardial Function, Perfusion, Hemodynamics and Heart Failure Symptoms in Patients With Hypertrophic Obstructive Cardiomyopathy.Hypertrophic CardiomyopathyDrug: Metoprolol Succinate;Drug: Placebo oral capsuleSteen Hvitfeldt PoulsenNULLRecruiting18 YearsN/AAll32Phase 2Denmark

113. Muscular dystrophy    [ 567 clinical trials,   442 drugs,   (DrugBank: 93 drugs),   55 drug target genes,   151 drug target pathways]
Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 567 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2009-009871-36-DE
(EUCTR)		06/08/2009Study within children with Duchenne Muscular DystrophyEffect and Safety of preventive Treatment with ACE-Inhibitor and Beta-Blocker on the onset of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy - DMD-Kardio Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]Trade Name: EnalHexal®, 5 mg
INN or Proposed INN: ENALAPRIL
Trade Name: EnaHexal®, 10mg
INN or Proposed INN: ENALAPRIL
Trade Name: MetoHEXAL® Succ ® 23,75 mg Retardtabletten
INN or Proposed INN: METOPROLOL SUCCINATE
Trade Name: MetoHEXAL® Succ ® 47,5 mg Retardtabletten
INN or Proposed INN: METOPROLOL SUCCINATE
Trade Name: MetoHEXAL® Succ ® 95 mg Retardtabletten
INN or Proposed INN: METOPROLOL SUCCINATE		Friedrich- Alexander- Universität Erlangen NürnbergNULLNot RecruitingFemale: no
Male: yes		Germany

193. Prader-Willi syndrome    [ 95 clinical trials,   104 drugs,   (DrugBank: 27 drugs),   50 drug target genes,   63 drug target pathways]
Searched query = "Prader-Willi syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 95 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2016-003694-18-CZ
(EUCTR)		18/01/201704/10/2016Safety and efficacy of tesofensine/metoprolol in subjects with Prader-Willi syndromeA double-blind, randomized, placebo-controlled, multiple-dose, multi-centre safety and efficacy study of co-administration of tesofensine/metoprolol in subjects with Prader-Willi syndrome (PWS) Second 12 weeks open label extension Prader Willi syndrome (PWS)
MedDRA version: 20.0;Level: PT;Classification code 10036476;Term: Prader-Willi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]		Product Name: Tesofensine
INN or Proposed INN: Tesofensine
Other descriptive name: TESOFENSINE
Trade Name: Metoprololsuccinat ”Orion” 25mg
INN or Proposed INN: metoprolol
Other descriptive name: METOPROLOL SUCCINATE		Saniona A/SNULLNot RecruitingFemale: yes
Male: yes		35Phase 2Hungary;Czech Republic

Back to top